Actively Recruiting
Evaluation of the Impact of the Clinical Pharmacist in the Initiation and Follow-up of Oral Therapies in Oncology
Led by Polyclinique Lyon Nord · Updated on 2025-08-26
90
Participants Needed
1
Research Sites
13 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the role of hospital pharmacists at the start of oral cancer treatments taken at home. This study aims to see how pharmaceutical monitoring at treatment initiation affects patient adherence, management of side effects, and overall treatment follow-up. The focus is on patients with solid tumors who begin oral therapy for cancer, excluding blood cancers. Participants are randomly assigned to one of two groups: one receiving a specialized pharmaceutical consultation at the hospital plus follow-up communication between hospital and community pharmacists, and the other receiving only the initial pharmaceutical consultation. The follow-up includes contacting the patient's local pharmacy to ensure treatment continuity and monitoring for issues such as missed refills or side effects. This approach compares standard pharmaceutical consultation with enhanced monitoring and coordination. During the study, patients will be assessed for treatment adherence at 3 and 6 months using the Girerd questionnaire. Researchers will track side effect management and treatment continuation through records kept by the pharmacists. The study emphasizes collaboration between hospital and community pharmacies to support patients throughout their oral cancer therapy. Participation involves regular monitoring and follow-up over several months to evaluate compliance and optimize care.
CONDITIONS
Brief Title
Evaluation of the Impact of the Clinical Pharmacist in Oral Therapies in Oncology.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient suffering from an oncological pathology (excluding hematological malignancies)
- Starting oral cancer treatment taken at home, either new or started less than 30 days ago
- Oral therapy dispensed through a pharmacy
- Patient able to continue oral therapy dispensed in pharmacies
You will not qualify if you...
- Patients with hematological malignancies
- Patients living in a hospital or care institution
- Patients treated for more than 30 days
- Patients receiving cancer treatment other than oral therapy (such as intravenous or subcutaneous treatments)
- Patients whose treatment after initiation is not dispensed in a pharmacy or community setting
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - Up to 6 months after treatment initiation
Participants receive specialized pharmaceutical consultation at the start of their oral cancer treatment, followed by ongoing follow-up consultations to support treatment adherence and manage any issues.
Initial consultation at treatment start and follow-up contacts around each treatment renewal
Duration - Up to 6 months after treatment initiation
Participants are observed for treatment adherence and clinical outcomes up to 6 months after starting oral therapy.
Assessments at 3 months and 6 months after treatment initiation
Trial Site Locations
Total: 1 location
1
Polyclinique Lyon Nord
Rillieux-la-Pape, France
Actively Recruiting
Research Team
M
Marion Mandon, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here